Brief: Puretech's Deupirfenidone Receives Orphan Drug Status from US FDA, EU for Pulmonary Fibrosis

Puretech Health

19/02/2026 17:37

Feb 19 (Reuters) - PureTech Health PLC PRTC.L:

PURETECH ANNOUNCES ORPHAN DRUG DESIGNATIONS GRANTED BY THE U.S. FOOD AND DRUG ADMINISTRATION AND EUROPEAN COMMISSION FOR DEUPIRFENIDONE (LYT-100) IN IDIOPATHIC PULMONARY FIBROSIS

Source text: ID:nBw7MfGhYa

Further company coverage: PRTC.L

 ((Reuters.Briefs@thomsonreuters.com;))